US 11,712,429 B2
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
Ian Osterloh, Kent (GB); Pierre Wicker, Mystic, CT (US); Rene Braeckman, Richboro, PA (US); Paresh Soni, Mystic, CT (US); and Jonathan Rowe, Waterford, CT (US)
Assigned to Amarin Pharmaceuticals Ireland Limited, Dublin (IE)
Filed by Amarin Pharmaceuticals Ireland Limited, Dublin (IE)
Filed on Nov. 13, 2020, as Appl. No. 17/97,555.
Application 17/097,555 is a continuation of application No. 16/702,236, filed on Dec. 3, 2019, abandoned.
Application 16/702,236 is a continuation of application No. 16/179,623, filed on Nov. 2, 2018, abandoned.
Application 16/179,623 is a continuation of application No. 13/990,316, abandoned, previously published as PCT/US2011/062247, filed on Nov. 28, 2011.
Claims priority of provisional application 61/417,691, filed on Nov. 29, 2010.
Prior Publication US 2021/0113513 A1, Apr. 22, 2021
Int. Cl. A61K 31/232 (2006.01); A61K 31/202 (2006.01); A61K 31/355 (2006.01); A61K 45/06 (2006.01); A61P 3/06 (2006.01); A61P 9/12 (2006.01); A61P 9/14 (2006.01); A61K 9/48 (2006.01)
CPC A61K 31/232 (2013.01) [A61K 31/202 (2013.01); A61K 31/355 (2013.01); A61K 45/06 (2013.01); A61P 3/06 (2018.01); A61P 9/12 (2018.01); A61P 9/14 (2018.01); A61K 9/4875 (2013.01)] 17 Claims
 
1. A method of reducing a number or size of arterial plaques in a subject on statin therapy, the method comprising administering to the subject about 4 g of ethyl icosapentate per day, wherein:
the subject has fasting baseline triglyceride levels between about 200 mg/dl to about 500 mg/dl,
the ethyl icosapentate is present in a pharmaceutical composition and the ethyl icosapentate comprises at least about 96 wt. % of all omega-3 fatty acids in the pharmaceutical composition, wherein:
the pharmaceutical composition further comprises about 0.1% to about 4%, by weight, of total fatty acids other than EPA and/or DHA, wherein the total fatty acid other than EPA and/or DHA comprises at least one selected from the group consisting of octadecatetraenoic acid (ODTA) or an ethyl ester thereof, nonaecapentaenoic acid (NDPA) or an ethyl ester thereof, eicosatetraenoic acid (ETA) or an ethyl ester thereof, and heneicosapentaenoic (HPA) or an ethyl ester thereof, and
the pharmaceutical composition comprises substantially no docosahexaenoic acid (DHA) or an ethyl ester thereof.